DEC 2019

InterAx Biotech and GPCR Therapeutics Inc collaborate for the identification of compounds with superior biological properties targeting GPCR heteromers using the InterAx systems biology platform

 

Seoul, South Korea and Villigen, Switzerland – 9th of December 2019
InterAx Biotech AG announced today that it has entered an agreement with GPCR Therapeutics, a biopharmaceutical company focusing on developing drugs targeting disease-specific GPCR heterodimers. “The long-standing in-house expertise on the biology of GPCR heteromers and chemokines at InterAx and the cutting-edge approach of GPCR Therapeutics in targeting relevant heteromers in cancer has resulted in an exciting collaboration. Our unique computational approach to characterize specific signaling patterns of relevant GPCR heteromers will help to identify compounds with superior biological properties”, says Maria Waldhoer, CSO at InterAx. “We are also delighted to be working with an uprising biopharmaceutical company in South Korea, as we are for the first time introducing our platform beyond European borders.”
“We are excited to have the opportunity to partner with InterAx to prioritize drug candidates targeting GPCR heteromers. We hope that combining our innovative platform to target cancer-specific GPCR heteromers with InterAx systems biology modeling will ultimately lead to major discoveries that will benefit patients,” says Dr. Dong Seung Seen, the CEO of GPCR Therapeutics, Inc.

About InterAx
InterAx Biotech AG is pioneering computational pharmacology for drug discovery. The Swiss company is uniquely positioned to assist drug candidate design and selection for G protein-coupled receptors in collaborative projects with Biotech and Pharma companies. InterAx applies mathematical models and simulations to in-house derived bioanalytical data in order to address the complexity of drug-induced cellular signaling mechanisms.
For more information, please visit www.interaxbiotech.com.

About GPCR Therapeutics
GPCR Therapeutics Inc. is a biopharmaceutical company focusing on developing drugs targeting disease-specific GPCR heteromers. The diversity of GPCR heterodimerizations and their modes of action represent an unprecedented challenge and opportunity to discover novel drug targets and develop new drugs with higher specificity and less side effects. By taking novel approaches to targeting GPCR heteromers, the south Korean company is developing innovative pharmaceuticals to address unmet medical needs.
For more information, please visit www.gpcr.co.kr.

Printer friendly version

SEPT 2019

Horizon 2020

European Union awards InterAx with Horizon 2020 SME Instrument Phase 2 for the integration of machine learning into the InterAx systems biology platform for drug discovery

 

Villigen – Switzerland, Brussels – Belgium, 25th September 2019 Villigen

InterAx Biotech AG today announces the support of the highly competitive Phase 2 European Union Horizon 2020 research and innovation program for Small to Medium-Sized Enterprise (SME) for its technology platform PICARD with a total project volume of 2.49M EUR. With the received funding, InterAx will expand both its technology development and boost its commercialization and market penetration efforts. 

Aurélien Rizk, CTO of InterAx Biotech explains: “The InterAx technology is a disruptive drug candidate-discovery platform that integrates a mathematical description of biological systems into drug exploration. This so-called systems biology approach is a first-of-its-kind technology that allows for advanced drug candidate selection. PICARD will allow us to now design lead molecules by integrating artificial intelligence into our systems biology platform. By doing this, we will be able to explore new chemical space and accelerate the discovery process of advanced lead molecules targeting G Protein-Coupled Receptors (GPCRs).” 

As for the commercial aspects of PICARD, InterAx will get support by the EC to further implement its commercialization plan. Rizk adds: “We have already entered the market with several customer projects and know that the PICARD platform will bring even more value to our Biotech and Pharma partners.”

The team thanks the European Commission for the trust received. 

The European Union’s Horizon 2020 research and innovation program supports breakthrough innovation projects with a market-creating potential. The SME instrument boosts fast company growth and market-creating innovation thanks to staged funding and ramped up business acceleration services.

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 880322.

For more information read the latest interview with Aurélien Rizk by Eugen Stamm.

 

Printer friendly version

AUG 2019

InterAx Biotech and Boehringer Ingelheim collaborate for enabling the in-depth characterization of drug candidates using the proprietary InterAx systems biology platform



Biberach, Germany and Villigen, Switzerland – 6th of August 2019

InterAx Biotech AG announced today that it has entered an agreement with Boehringer Ingelheim to enable the in-depth characterization of drug candidates using the proprietary InterAx systems biology platform. InterAx and Boehringer will collaborate to characterize drug candidates for an undisclosed target. “We are looking forward to combining our unique technology with the expertise of Boehringer Ingelheim to identify compounds with superior biological properties for one of Boehringer’s target receptors”, says Maria Waldhoer, CSO at InterAx. Financial terms of the partnership were not disclosed.

About InterAx
InterAx Biotech AG is pioneering computational pharmacology for drug discovery. The Swiss company is uniquely positioned to assist drug candidate design and selection for G protein-coupled receptors in collaborative projects with Biotech and Pharma companies. InterAx applies mathematical models and simulations to in-house derived bioanalytical data in order to address the complexity of drug-induced cellular signaling mechanisms.

 

Printer friendly version

MAY 2019

Next EU Training Network ONCORNET2.0 on oncogenic GPCR networks

 

The EU has granted 4M euro to Martine Smit and Jacqueline van Muijlwijk (Medicinal Chemistry, AIMMS, Faculty of Science, Vrije Universiteit Amsterdam) and colleagues from academia and SMEs from the Netherlands, France, Germany, Spain, UK and Switzerland.

ONCORNET2.0 builds on the success of ONCORNET (Oncogenic GPCR Network of Excellence and Training), a first-in-kind ITN in GPCR drug discovery that has successfully delivered scientific advance and training to talented early stage researchers (ESRs) (www.oncornet.eu). ONCORNET2.0 will incorporate recent scientific and technological breakthroughs to understand and target two oncogenic G protein-coupled receptors (GPCRs); the chemokine receptors CXCR4 and ACKR3 (CXCR7). These are highly expressed in multiple tumours but their role in cancer progression remains poorly understood. We will develop new strategies for CXCR4/ACKR3 modulation and investigate their effects on oncogenic responses, to yield key new knowledge and potential leads for drug development.

ONCORNET2.0 will bring together the leading GPCR research groups in Europe and will educate the next generation of young researchers (15 PhD students) by a multi-disciplinary training. This programme integrates both research (e.g. drug discovery, proteomics, imaging) and transferable (e.g. entrepreneurship, academic writing, media training) skill sets through blended learning. This will ensure that the ESRs can effectively operate in today’s drug discovery programs and will increase European competitiveness in the field of drug discovery.

Partners
Academic groups:

  • Martine Smit, Jacqueline van Muijlwijk, Rob Leurs, Iwan de Esch (Vrije Universiteit Amsterdam, NL)
  • Steve Hill, Meritxell Canals, Steve Briddon (University of Nottingham, UK)
  • Philippe Marin, Thierry Durroux, Sébastien Granier, Jean Philippe Pin (CNRS, FR)
  • Martin Lohse (Max-Delbruck-Centrum für Molekulare Medizin, DE)
  • Carsten Hoffmann (Universitätsklinikum Jena, DE)
  • Françoise Bachelerie, Géraldine Schlecht-Louf (INSERM, FR)
  • Federico Mayor, Petronila Penela (Universidad Autónoma de Madrid, ES)
  • Graeme Milligan, Gerry Graham (University of Glasgow, UK)

SMEs:
  • QVQ (Raimond Heukers, NL)
  • InterAx Biotech (Maria Waldhoer, CH)

Other partner organisations are: Cisbio/ PerkinElmer (Eric Trinquet, FR), Sosei Heptares (Chris de Graaf, UK), ALMAC (Alastair Hay, UK), Promega (Rachel Ohana, Keith Wood, US) and Learning By Simulation (LBS) (Leon Delbressine, NL).

APR 2019

InterAx Biotech and Lundbeck A/S entered an agreement to enable the in-depth characterization of drug candidates using the proprietary InterAx systems biology platform

 

Switzerland – Denmark, April 2019 Villigen
InterAx Biotech AG announced today that it has entered an agreement with Lundbeck A/S to enable the in-depth characterization of drug candidates using the proprietary InterAx systems biology platform. InterAx and Lundbeck will combine their expertise in the characterization of drug candidates for an undisclosed target. “We are delighted to assist Lundbeck in their quest to identify compounds with superior biological properties for their target receptor with our unique technology”, says Maria Waldhoer, CSO at InterAx. Financial terms of the partnership were not disclosed.

About Lundbeck
H. Lundbeck A/S (LUN.CO, LUN DC, HLUYY) is a global pharmaceutical company specialized in psychiatric and neurological disorders. For more than 70 years, Lundbeck A/S has been at the forefront of research within neuroscience.

About InterAx
InterAx Biotech AG is pioneering computational pharmacology for drug discovery. The Swiss company is uniquely positioned to assist drug candidate design and selection for G protein-coupled receptors in collaborative projects with Biotech and Pharma companies. InterAx applies mathematical models and simulations to in house-derived bioanalytical data in order to address the complexity of drug-induced cellular signaling mechanisms.

FEB 2019

InterAx Biotech received the Seal of Excellence by the European Commission

 

February 2019, Switzerland-Belgium : InterAx is proud to announce that we received the Seal of Excellence by the European Commission, as the institution managing Horizon 2020, the EU Framework Programme for Research and Innovation 2014-2020 for its Disruptive GPCR Lead Discovery Platform Delivering New and Safer Therapeutics.

JAN 2019

InterAx Biotech closed a financing round of CHF 3 million

 

January 2019, Switzerland : InterAx, a Biotech company pioneering computational pharmacology for drug discovery, has closed a financing round of CHF 3 million. The investment round was led by Falcon III Ventures and investiere. The new funds will be used to accelerate commercialization of the technology platform which enables intelligent drug candidate design and selection. InterAx appoints Dr. Bettina Ernst as a new member of the board of directors. She brings in additional extensive and valuable experience from the biotech and pharmaceutical industry.